Major R&D Pipeline: 3ADCs

FY2021 News Flow Daiichi-Sankyo As of July 2021 Planned publications WCLC (Sep 8-14) Dato-DXd TROPION-Pan Tumor01: Ph1 NSCLC cohort Updated data ESMO (Sep 16-21) EnhertuⓇ DESTINY-Lung01: HER2mutated/overexpressing NSCLC, 2L, Ph2 HER2 mutated cohort data* DESTINY-Breast01: HER2 positive BC, 3L, Ph2 Updated OS data TROPION-PanTumor01: Ph1 NSCLC cohort Sub-analysis of patients with actionable mutations* Regulatory decisions Atrial fibrillation in the very elderly Lixiana® Japan: FY2021 Q2 Ischemic stroke Japan: FY2021 Q3 EfientⓇ • Planned regulatory submissions Enhertu DS-3201 DESTINY-Gastric01/02: HER2 positive GC, 2/3L, Ph2 Europe: FY2021 2H Registrational Ph2: ATL/L Japan: FY2021 2H Dato-DXd Solid tumor Ph1/2 DS-7300 Ph1 dose escalation data * Final decision for the acceptance of late breaking abstract will be made after Aug 17 Key data readouts EnhertuⓇ Quizartinib DESTINY-Breast03: HER2 positive BC, 2L, Ph3 FY2021 Q2 DESTINY-Breast04: HER2 low BC, post chemo, Ph3 FY2021 Q4 QUANTUM-First: AML, 1L, Ph3 FY2021 Q3 Underlined: New or updated from ASCO Highlight AML: acute myeloid leukemia, ATL: adult T-cell leukemia/lymphoma, BC: breast cancer, NSCLC: non small cell lung cancer, OS: overall survival 31

View entire presentation